This review synthesizes recent molecular insights into how Nrf2–Keap1 signaling governs NLRP3 inflammasome activity, delineates the consequences of axis dysregulation for mitochondrial integrity and dopaminergic survival and critically appraises emerging pharmacological approaches aimed at restoring this balance to modify PD progression. The gene discussed is NFE2L2; the disease is Parkinson disease.